Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis

Pengcheng Luo, Hsin Hsin Chang, Yiqiang Zhou, Shali Zhang, Sung Hee Hwang, Christophe Morisseau, Cong Yi Wang, Edward W. Inscho, Bruce D. Hammock, Mong Heng Wang

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Soluble epoxide hydrolase (sEH) is an enzyme involved in the metabolism of endogenous inflammatory and antiapoptotic mediators. However, the roles of sEH in diabetes and the pancreas are unknown. Our aims were to determine whether sEH is involved in the regulation of hyperglycemia in diabetic mice and to investigate the reasons for the regulation of insulin secretion by sEH deletion or inhibition in islets. We used two separate approaches, targeted disruption of Ephx2 gene [sEH knockout (KO)] and a selective inhibitor of sEH [trans-4-[4-(3-adamantan-1-ylureido)-cyclohexyloxy]-benzoic acid (t-AUCB)], to assess the role of sEH in glucose and insulin homeostasis in streptozotocin (STZ) mice. We also examined the effects of sEH KO or t-AUCB on glucose-stimulated insulin secretion (GSIS) and intracellular calcium levels in islets. Hyperglycemia in STZ mice was prevented by both sEH KO and t-AUCB. In addition, STZ mice with sEH KO had improved glucose tolerance. More important, when insulin levels were assessed by hyperglycemic clamp study, sEH KO was found to promote insulin secretion. In addition, sEH KO and t-AUCB treatment augmented islet GSIS. Islets with sEH KO had a greater intracellular calcium influx when challenged with high glucose or KCl in the presence of diazoxide. Moreover, sEH KO reduced islet cell apoptosis in STZ mice. These results show not only that sEH KO and its inhibition prevent hyperglycemia in diabetes, but also that sEH KO enhances islet GSIS through the amplifying pathway and decreases islet cell apoptosis in diabetes.

Original languageEnglish (US)
Pages (from-to)430-438
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume334
Issue number2
DOIs
StatePublished - Aug 1 2010

Fingerprint

Epoxide Hydrolases
Hyperglycemia
Insulin
Apoptosis
Streptozocin
Glucose
Islets of Langerhans
Calcium
Diazoxide

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis. / Luo, Pengcheng; Chang, Hsin Hsin; Zhou, Yiqiang; Zhang, Shali; Hwang, Sung Hee; Morisseau, Christophe; Wang, Cong Yi; Inscho, Edward W.; Hammock, Bruce D.; Wang, Mong Heng.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 334, No. 2, 01.08.2010, p. 430-438.

Research output: Contribution to journalArticle

Luo, Pengcheng ; Chang, Hsin Hsin ; Zhou, Yiqiang ; Zhang, Shali ; Hwang, Sung Hee ; Morisseau, Christophe ; Wang, Cong Yi ; Inscho, Edward W. ; Hammock, Bruce D. ; Wang, Mong Heng. / Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis. In: Journal of Pharmacology and Experimental Therapeutics. 2010 ; Vol. 334, No. 2. pp. 430-438.
@article{98b4be33f59f4a8fbd6d9caee5376c05,
title = "Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis",
abstract = "Soluble epoxide hydrolase (sEH) is an enzyme involved in the metabolism of endogenous inflammatory and antiapoptotic mediators. However, the roles of sEH in diabetes and the pancreas are unknown. Our aims were to determine whether sEH is involved in the regulation of hyperglycemia in diabetic mice and to investigate the reasons for the regulation of insulin secretion by sEH deletion or inhibition in islets. We used two separate approaches, targeted disruption of Ephx2 gene [sEH knockout (KO)] and a selective inhibitor of sEH [trans-4-[4-(3-adamantan-1-ylureido)-cyclohexyloxy]-benzoic acid (t-AUCB)], to assess the role of sEH in glucose and insulin homeostasis in streptozotocin (STZ) mice. We also examined the effects of sEH KO or t-AUCB on glucose-stimulated insulin secretion (GSIS) and intracellular calcium levels in islets. Hyperglycemia in STZ mice was prevented by both sEH KO and t-AUCB. In addition, STZ mice with sEH KO had improved glucose tolerance. More important, when insulin levels were assessed by hyperglycemic clamp study, sEH KO was found to promote insulin secretion. In addition, sEH KO and t-AUCB treatment augmented islet GSIS. Islets with sEH KO had a greater intracellular calcium influx when challenged with high glucose or KCl in the presence of diazoxide. Moreover, sEH KO reduced islet cell apoptosis in STZ mice. These results show not only that sEH KO and its inhibition prevent hyperglycemia in diabetes, but also that sEH KO enhances islet GSIS through the amplifying pathway and decreases islet cell apoptosis in diabetes.",
author = "Pengcheng Luo and Chang, {Hsin Hsin} and Yiqiang Zhou and Shali Zhang and Hwang, {Sung Hee} and Christophe Morisseau and Wang, {Cong Yi} and Inscho, {Edward W.} and Hammock, {Bruce D.} and Wang, {Mong Heng}",
year = "2010",
month = "8",
day = "1",
doi = "10.1124/jpet.110.167544",
language = "English (US)",
volume = "334",
pages = "430--438",
journal = "The Journal of pharmacology and experimental therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis

AU - Luo, Pengcheng

AU - Chang, Hsin Hsin

AU - Zhou, Yiqiang

AU - Zhang, Shali

AU - Hwang, Sung Hee

AU - Morisseau, Christophe

AU - Wang, Cong Yi

AU - Inscho, Edward W.

AU - Hammock, Bruce D.

AU - Wang, Mong Heng

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Soluble epoxide hydrolase (sEH) is an enzyme involved in the metabolism of endogenous inflammatory and antiapoptotic mediators. However, the roles of sEH in diabetes and the pancreas are unknown. Our aims were to determine whether sEH is involved in the regulation of hyperglycemia in diabetic mice and to investigate the reasons for the regulation of insulin secretion by sEH deletion or inhibition in islets. We used two separate approaches, targeted disruption of Ephx2 gene [sEH knockout (KO)] and a selective inhibitor of sEH [trans-4-[4-(3-adamantan-1-ylureido)-cyclohexyloxy]-benzoic acid (t-AUCB)], to assess the role of sEH in glucose and insulin homeostasis in streptozotocin (STZ) mice. We also examined the effects of sEH KO or t-AUCB on glucose-stimulated insulin secretion (GSIS) and intracellular calcium levels in islets. Hyperglycemia in STZ mice was prevented by both sEH KO and t-AUCB. In addition, STZ mice with sEH KO had improved glucose tolerance. More important, when insulin levels were assessed by hyperglycemic clamp study, sEH KO was found to promote insulin secretion. In addition, sEH KO and t-AUCB treatment augmented islet GSIS. Islets with sEH KO had a greater intracellular calcium influx when challenged with high glucose or KCl in the presence of diazoxide. Moreover, sEH KO reduced islet cell apoptosis in STZ mice. These results show not only that sEH KO and its inhibition prevent hyperglycemia in diabetes, but also that sEH KO enhances islet GSIS through the amplifying pathway and decreases islet cell apoptosis in diabetes.

AB - Soluble epoxide hydrolase (sEH) is an enzyme involved in the metabolism of endogenous inflammatory and antiapoptotic mediators. However, the roles of sEH in diabetes and the pancreas are unknown. Our aims were to determine whether sEH is involved in the regulation of hyperglycemia in diabetic mice and to investigate the reasons for the regulation of insulin secretion by sEH deletion or inhibition in islets. We used two separate approaches, targeted disruption of Ephx2 gene [sEH knockout (KO)] and a selective inhibitor of sEH [trans-4-[4-(3-adamantan-1-ylureido)-cyclohexyloxy]-benzoic acid (t-AUCB)], to assess the role of sEH in glucose and insulin homeostasis in streptozotocin (STZ) mice. We also examined the effects of sEH KO or t-AUCB on glucose-stimulated insulin secretion (GSIS) and intracellular calcium levels in islets. Hyperglycemia in STZ mice was prevented by both sEH KO and t-AUCB. In addition, STZ mice with sEH KO had improved glucose tolerance. More important, when insulin levels were assessed by hyperglycemic clamp study, sEH KO was found to promote insulin secretion. In addition, sEH KO and t-AUCB treatment augmented islet GSIS. Islets with sEH KO had a greater intracellular calcium influx when challenged with high glucose or KCl in the presence of diazoxide. Moreover, sEH KO reduced islet cell apoptosis in STZ mice. These results show not only that sEH KO and its inhibition prevent hyperglycemia in diabetes, but also that sEH KO enhances islet GSIS through the amplifying pathway and decreases islet cell apoptosis in diabetes.

UR - http://www.scopus.com/inward/record.url?scp=77954902049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954902049&partnerID=8YFLogxK

U2 - 10.1124/jpet.110.167544

DO - 10.1124/jpet.110.167544

M3 - Article

C2 - 20439437

AN - SCOPUS:77954902049

VL - 334

SP - 430

EP - 438

JO - The Journal of pharmacology and experimental therapeutics

JF - The Journal of pharmacology and experimental therapeutics

SN - 0022-3565

IS - 2

ER -